Recruiting Trials

tuberculosis

TB043 Tuberculosis Study – A BCG challenge study in healthy adults to help develop TB vaccines.  If you are aged 18-50, in good health, and have never received the BCG vaccine, you may be eligible to participate.  The study involves 9-12 visits over a period of around 6 months. Participants will be reimbursed for their time and travel from £705 to £750.

Click here for more information. 

RIFT VALLEY FEVER

RVF001 Rift Valley Fever Vaccine Study - A phase I study to determine the safety and immunogenicity of the Rift Valley Fever (RVF) vaccine in healthy adult participants.  If you are aged 18-50 and are in good health, you may be eligible to participate.  The trial will involve 8 visits over a period of 3 months and participants will receive around £370 on completion of the study. 

Click here for more information.

COVID-19 Vaccine Internasal Study

The Jenner Institute is conducting a study to determine the safety, tolerability and immunogenicity of intranasal administration of the COVID vaccine ChAdOx1 nCOV-19 in healthy UK adults as a booster after full intramuscular vaccination.

Why Are We Conducting This Study?

This study will help us learn:

• If the Oxford Vaccine is safe and effective when administered intranasally

How will I be Making a Difference?

This study could help us develop of a safe and effective vaccine against COVID-19.

Its findings could assist with rapid deployment of the Oxford Vaccine. 

How do I get involved?

If you are healthy, aged between 30-55 years old, and have received both doses of either the Oxford/AZ vaccine (ChAdOX1 nCoV-19) or the Pfizer vaccine (BNT162b2) you may be eligible to participate. 

Click here for more information. 

Will I be Paid?

You will be compensated approximately £325-490 for your time, travel and inconvenience.

EBL07 Ebola Vaccine Study

Using the same technology we used for the Oxford/AstraZeneca COVID-19 vaccine, Prof Teresa Lambe’s team at the Jenner Institute is conducting a study of a new Ebola vaccine that targets the two deadliest Ebolavirus species.

Why Are We Conducting This Study?

The study will help us learn more about the safety and tolerability of ChAdOx1 BiEBOV vaccine in healthy volunteers.

How will I be Making a Difference?

It is hoped that the information gained from this study will contribute to the development of a further safe and effective vaccine to protect at-risk populations from Ebola virus disease.

How do I get involved?

If you are 18-55 years old you may be eligible to participate.

For information about COV001 and COV002 COVID-19 Oxford Vaccine studies, please visit: https://covid19vaccinetrial.web.ox.ac.uk. Recruitment for these studies is now complete.